[Recent advances in treatment of viral pneumonia using Chinese patent medicine].

2019-nCoV COVID-19 immunity inflammation pulmonary fibrosis viral pneumonia viral replication

Journal

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
ISSN: 1001-5302
Titre abrégé: Zhongguo Zhong Yao Za Zhi
Pays: China
ID NLM: 8913656

Informations de publication

Date de publication:
Apr 2020
Historique:
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 6 6 2020
Statut: ppublish

Résumé

Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon.

Identifiants

pubmed: 32489027
doi: 10.19540/j.cnki.cjcmm.20200312.502
doi:

Substances chimiques

Nonprescription Drugs 0

Types de publication

Journal Article Review

Langues

chi

Sous-ensembles de citation

IM

Pagination

1509-1514

Auteurs

Tao Wang (T)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Li-Feng Han (LF)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Yue-Fei Wang (YF)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Lin Miao (L)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Jian Yang (J)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Jun-Hua Zhang (JH)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Xiu-Mei Gao (XM)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Bo-Li Zhang (BL)

Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH